A practical reference on prohibited list: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Speer's Monster-Building (German: Monsterbau) was to be the capital's most important and impressive building in terms of its size and symbolism. Visually it was to have been the architectural centrepiece of Berlin as the world capital (Welthauptstadt). Its dimensions were so large that it would have dwarfed every other structure in Berlin, including those on the north-south axis itself. The oculus of the building's dome, 46 metres (151 ft) in diameter, would have accommodated the entire rotunda of Hadrian's Pantheon and the dome of St. Peter's Basilica. The dome of the Volkshalle was to rise from a massive granite podium 315 by 315 metres (1,033 ft × 1,033 ft) and 74 metres (243 ft) tall, to a total inclusive height of 290 metres (950 ft). The diameter of the dome, 250 metres (820 ft), was to be exceeded, much to Speer's annoyance, by the diameter of Giesler's new domed railway station at the east end of Munich's east–west axis. It was to be 15 metres (49 ft) greater in diameter than Speer's Volkshalle. The resemblance of the Volkshalle to the Pantheon is far more obvious when their interiors are compared. The large niche 50 by 28 metres (164 ft × 92 ft) at the north end of the Volkshalle was to be surfaced with gold mosaic and to enclose an eagle 24 metres (79 ft) tall, beneath which was situated Hitler's tribunal.
== Functions in animals == Selenium is an essential micronutrient in mammals, but is also recognized as toxic in excess. Selenium exerts its biological functions through selenoproteins, which contain the amino acid selenocysteine. Twenty-five selenoproteins are encoded in the human genome.
Another difference between baclofen and sodium oxybate is that baclofen has a much longer elimination half-life and duration of action in comparison (half-life 3–4 hours versus 0.5–1.0 hours, respectively).
Chlorination occurs at the amino acyl-PCP level during the biosynthesis, prior to phenolic oxidative coupling, with the possibility of tyrosine or β-hydroxytyrosine being the substrate of chlorination. Hydroxylation of the tyrosine residue of module 6 also occurs in trans during the assembly of the heptapeptide backbone.
Sources: en.wikipedia.org
== International presence == Viscofan exports a large part of its products to other markets and is currently present in over 100 countries. It has production centers in 13 countries and maintains commercial offices in 15 countries.
Alison Elizabeth Larter (born February 28, 1976), is an American actress and former model. She portrayed fictional model Allegra Coleman in a 1996 Esquire magazine hoax and took on guest roles on several television shows in the 1990s. Her film debut in Varsity Blues (1999) was followed by a role in the horror film House on Haunted Hill (1999). She portrayed Clear Rivers in the Final Destination franchise (2000–2003) establishing her as a scream queen. Larter played supporting roles in Legally Blonde (2001), Jay and Silent Bob Strike Back (2001), and the romantic comedy A Lot Like Love (2005), and main roles in the Bollywood movie Marigold (2007) and the thriller Obsessed (2009). She achieved wider recognition for playing the dual roles of Niki Sanders and Tracy Strauss on the science fiction drama series Heroes (2006–2010) on NBC, and for portraying video game heroine Claire Redfield in three films of the Resident Evil film series (2007–2016). Larter costars as Angela Norris in the Paramount+ drama series Landman (2024). As of April 2017, Larter's films have grossed over $1.31 billion worldwide. Her presence in the media is reinforced by her appearances in lists compiled by Maxim, FHM, and Stuff as well as People's "Best Dressed List" in 2007. She published a cookbook, Kitchen Revelry: A Year of Festive Menus from My Home to Yours, in September 2013.
However, there is no real demand in chemistry, physics, or engineering for isolating 234U, and the small amounts that may be wanted for research can be separated chemically from plutonium-238 that have been aged enough to accumulate its alpha decay product, which is 234U. Enriched uranium contains more 234U than natural uranium as a byproduct of the uranium enrichment process aimed at obtaining uranium-235, which concentrates lighter isotopes even more strongly than it does 235U. IAEA research paper TECDOC-1529 concludes the 234U content of enriched fuel is directly proportional to the degree of 235U—enrichment with 2% 235U resulting in 150 g 234U/ton HM (heavy metals, special meaning, relating to nuclear fuels), and the most common 4.5% 235U enrichment resulting in 400 g 234U/ton HM. The increased percentage of 234U in enriched natural uranium is not harmful to the operation of current nuclear reactors. Uranium-234 has a neutron-capture cross section of about 100 barns for thermal neutrons, and about 700 barns for its resonance integral—the average of neutrons having a range of intermediate energies. In a nuclear reactor non-fissile isotopes 234U and 238U both capture a neutron, thereby breeding fissile isotopes 235U and 239Pu, respectively. 234U is converted to 235U more easily and therefore at a greater rate than 238U is to 239Pu (via neptunium-239) because 238U has a much smaller neutron-capture cross section of just 2.7 barns.
On 27 February at 3:38 p.m. EST (11:08 p.m. IRST), Trump, traveling on Air Force One to Texas, authorized Operation Epic Fury. US missiles, drones, and Israeli fighter jets began striking Iran the next day, around 9:45 am. IRST (1:15 am. EST). The strikes took place during negotiations over Iran's nuclear program, and coincided with the holy month of Ramadan. The operation was codenamed Operation Roaring Lion by Israel. The Israeli Air Force (IAF) said it struck 500 military targets in Iran in the largest combat sortie in its history. Iranian naval vessels were also targeted. Israel said it used over 1,200 bombs in 24 hours. US strikes were carried out by planes based around the Middle East and from aircraft carriers.
(2026), who recover the studied species as closely related to the American mastodon. Sanders, Ji & Jablonski (2026) describe fossil material of Stegodon zhaotongensis from the Miocene strata of the Zhaotong Formation at the Shuitangba site (Yunnan, China), reaffirm the validity of the species, and interpret its anatomical features as consistent with origination of stegodonts from stegolophodonts in Asia. Liu et al. (2026) report the first discovery of fossil material of Stegodon from the late Pliocene or early Pleistocene strata from the Shandong Province (China), referred to the species Stegodon chiai. A study on the chemical composition of teeth of Gomphotherium angustidens from the Miocene (Langhian) strata from Quinta da Farinheira (Portugal), providing evidence of seasonal changes in the diet of the studied proboscidean and probable evidence of geophagia during fixed times of the year, is published by Coimbra et al. (2026). Han et al. (2026) report the discovery of a molar of a member of the genus Gomphotherium from the Miocene strata of the Jinsu Formation (North Korea), extending known geographical distribution of members of this genus in Asia. New fossil material of Notiomastodon platensis is described from the Lujanian strata of the La Chumbiada Member of the Lujan Formation (Buenos Aires Province, Argentina) by Prado et al. (2026).
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.